Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 06, 2025 | May 08, 2025 |
| ORACLE CORPORCL · Entity 2805 | Director | September 29, 2026 | October 02, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | March 06, 2023 | March 08, 2023 |
| TENET HEALTHCARE CORPTHC · Entity 2563 | Director | May 22, 2025 | May 28, 2025 |
| XEROX CORPXRX · Entity 12016 | Director | January 12, 2018 | January 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date May 06, 2025 · Filed May 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 16,499 |
Reported balance
After 2025-05-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-06 · Grant · Acquired 7,183 · Balance 16,499 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2: Total includes the automatic reinvestment of dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
F2: Total includes the automatic reinvestment of dividends.
ORACLE CORP
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Stephen H. Rusckowski Living Trust | 25,390 |
Reported balance
After 2026-09-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-29 · Purchase · Acquired 25,000 · Balance 25,390 F1: This transaction was executed in multiple trades at prices ranging from $138.96 to $139.74. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 60 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 60 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $138.96 to $139.74. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
QUEST DIAGNOSTICS INC
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 389,597 |
Last balance in matching sequence
After 2023-03-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-03-06 · Grant · Acquired 82,631 · Balance 428,201 F1: Represents an award of restricted share units granted on February 25, 2013. F2: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). Row 2 · 2023-03-06 · Tax withholding · Disposed 38,604 · Balance 389,597 F1: Represents an award of restricted share units granted on February 25, 2013. F3: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units granted on February 25, 2013.
F2: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d).
F3: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.
TENET HEALTHCARE CORP
Report date May 22, 2025 · Filed May 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,233 |
Reported balance
After 2025-05-23 transaction · row 1
1 source rowRow 1 · 2025-05-23 · Exercise / conversion · Acquired 1,551 · Balance 5,233 F1: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-05-22 | Direct | 1,333 |
Reported balance
After 2025-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-22 · Grant · Acquired 1,333 · Balance 1,333 F2: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2025-05-23 | Direct | 0 |
Reported balance
After 2025-05-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-23 · Exercise / conversion · Disposed 1,551 · Balance 0 F1: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock.
F2: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares.
XEROX CORP
Report date January 12, 2018 · Filed January 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table I · non-derivative | Direct | 17,952 |
Reported balance
After 2018-01-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-01-12 · Grant · Acquired 2,793 · Balance 17,952 F1: Each DSU represent the right to receive one share of common stock upon the reporting person's termination of service as a director. F2: This amount includes 103 shares paid on 7/31/17 and 113 shares paid on 10/31/17 from the reinvestment of dividend equivalents paid on Deferred Stock Units held as of 6/30/2017 and 9/29/2017, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Each DSU represent the right to receive one share of common stock upon the reporting person's termination of service as a director.
F2: This amount includes 103 shares paid on 7/31/17 and 113 shares paid on 10/31/17 from the reinvestment of dividend equivalents paid on Deferred Stock Units held as of 6/30/2017 and 9/29/2017, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2019 Filed Feb 26, 2019 01:04 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,215 | $88.39 | $195,783.85 |
DisclosureSEC source: 0001022079-19-000047 · wf-form4_155114303022201.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,400 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 213,704 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000026 · wf-form4_155070558946491.xml · derivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,704 Underlying: Common Stock · 213,704 shares Expires 2029-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 17,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000026 · wf-form4_155070558946491.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,615 F1 · shares: Represents an award of restricted share units. Read SEC document |
| May 25, 2018 Filed May 29, 2018 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 168,490 | $56.12 Strike: $56.12 | $9,455,658.80 |
DisclosureSEC source: 0001022079-18-000135 · wf-form4_152762636527883.xml · derivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,490 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 20, 2018. F2 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 25, 2014, the second on February 25, 2015 and the final on February 25, 2016. Read SEC document |
| May 25, 2018 Filed May 29, 2018 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 168,490 | $107.00 | $18,028,430.00 |
DisclosureSEC source: 0001022079-18-000135 · wf-form4_152762636527883.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,069 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 20, 2018. Read SEC document |
| May 25, 2018 Filed May 29, 2018 20:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 168,490 | $56.12 | $9,455,658.80 |
DisclosureSEC source: 0001022079-18-000135 · wf-form4_152762636527883.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 20, 2018. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 00:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 23,428 | $101.00 | $2,366,228.00 |
DisclosureSEC source: 0001022079-18-000091 · wf-form4_152038337574832.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,069 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 00:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 43,789 | $101.00 | $4,422,689.00 |
DisclosureSEC source: 0001022079-18-000091 · wf-form4_152038337574832.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,497 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 23, 2015, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,017 | $101.43 | $306,014.31 |
DisclosureSEC source: 0001022079-18-000072 · wf-form4_151994226136351.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,708 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:41 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 5,263 | $101.43 | $533,826.09 |
DisclosureSEC source: 0001022079-18-000055 · wf-form4_151976765840559.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,725 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 21:41 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,094 | $102.69 | $215,032.86 |
DisclosureSEC source: 0001022079-18-000055 · wf-form4_151976765840559.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,988 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 19, 2018 Filed Feb 22, 2018 00:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 171,061 | $0.00 Strike: $103.57 | $0.00 |
DisclosureSEC source: 0001022079-18-000022 · wf-form4_151925938624594.xml · derivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,061 Underlying: Common Stock · 171,061 shares Expires 2028-02-19 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 19, 2018 Filed Feb 22, 2018 00:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 14,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-18-000022 · wf-form4_151925938624594.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,082 F1 · shares: Represents an award of restricted share units. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 106,840 | $58.18 Strike: $58.18 | $6,215,417.00 |
DisclosureSEC source: 0001022079-18-000011 · wf-form4_151743439318187.xml · derivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,840 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. F2 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on May 1, 2013, the second on May 1, 2014 and the final on May 1, 2015. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 106,840 | $107.00 | $11,431,880.00 |
DisclosureSEC source: 0001022079-18-000011 · wf-form4_151743439318187.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,116 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 106,840 | $58.18 | $6,215,417.00 |
DisclosureSEC source: 0001022079-18-000011 · wf-form4_151743439318187.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 17:51 UTC | XEROX CORP XRX · Entity 12016 | GrantDeferred Stock Units | 2,793 | $32.23 | $90,004.43 |
DisclosureSEC source: 0001127602-18-001768 · form4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,952 F1 · security: Each DSU represent the right to receive one share of common stock upon the reporting person's termination of service as a director. F2 · balance_after: This amount includes 103 shares paid on 7/31/17 and 113 shares paid on 10/31/17 from the reinvestment of dividend equivalents paid on Deferred Stock Units held as of 6/30/2017 and 9/29/2017, respectively. Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 22:18 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,302 | $58.18 Strike: $58.18 | $308,443.85 |
DisclosureSEC source: 0001022079-17-000178 · wf-form4_150534109370130.xml · derivative · entry 6 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,840 Underlying: Common Stock · 5,302 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. F4 · derivative.exercise_date: The options vested in three annual installments beginning with the first on May 1, 2013, the second on May 1, 2014 and the final on May 1, 2015. Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 22:18 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 5,302 | $108.12 | $573,236.33 |
DisclosureSEC source: 0001022079-17-000178 · wf-form4_150534109370130.xml · nonDerivative · entry 4 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,116 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $108.00 to $108.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 22:18 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 5,302 | $58.18 | $308,443.85 |
DisclosureSEC source: 0001022079-17-000178 · wf-form4_150534109370130.xml · nonDerivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:18 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 53,933 | $58.18 Strike: $58.18 | $3,137,552.28 |
DisclosureSEC source: 0001022079-17-000178 · wf-form4_150534109370130.xml · derivative · entry 5 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,142 Underlying: Common Stock · 53,933 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. F4 · derivative.exercise_date: The options vested in three annual installments beginning with the first on May 1, 2013, the second on May 1, 2014 and the final on May 1, 2015. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:18 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 53,933 | $108.16 | $5,833,609.01 |
DisclosureSEC source: 0001022079-17-000178 · wf-form4_150534109370130.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,116 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $108.00 to $108.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:18 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 53,933 | $58.18 | $3,137,552.28 |
DisclosureSEC source: 0001022079-17-000178 · wf-form4_150534109370130.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,525 | $58.18 Strike: $58.18 | $146,891.88 |
DisclosureSEC source: 0001022079-17-000174 · wf-form4_150481683383336.xml · derivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,075 Underlying: Common Stock · 2,525 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. F4 · derivative.exercise_date: The options vested in three annual installments beginning with the first on May 1, 2013, the second on May 1, 2014 and the final on May 1, 2015. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 2,525 | $108.03 | $272,768.18 |
DisclosureSEC source: 0001022079-17-000174 · wf-form4_150481683383336.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,116 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $108.00 to $108.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 2,525 | $58.18 | $146,891.88 |
DisclosureSEC source: 0001022079-17-000174 · wf-form4_150481683383336.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 3, 2017. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 18:11 UTC | XEROX CORP XRX · Entity 12016 | GrantDeferred Stock Units | 3,063 | $29.39 | $90,021.57 |
DisclosureSEC source: 0001127602-17-023750 · form4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,943 F1 · security: Each DSU represent the right to receive one share of common stock upon the reporting person's termination of service as a director. F2 · balance_after: On June 14, 2017, Xerox Corporation effected a 1-for-4 reverse stock split of its Common Stock. The amount of securities reported in this Form 4 has been adjusted to reflect the reverse stock split. F3 · balance_after: This amount includes 73 shares paid on 1/31/17 and 100 shares paid on 4/28/17 from the reinvestment of dividend equivalents paid on Deferred Stock Units held as of 12/15/2016 and 3/31/2017, respectively. These dividend equivalents have been adjusted to reflect the effects of reverse stock split. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 22:00 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 26,891 | $98.12 | $2,638,544.92 |
DisclosureSEC source: 0001022079-17-000090 · wf-form4_148857838844457.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,888 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 22:00 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 47,934 | $98.12 | $4,703,284.08 |
DisclosureSEC source: 0001022079-17-000090 · wf-form4_148857838844457.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,682 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 13, 2014, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:47 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,163 | $96.42 | $304,976.46 |
DisclosureSEC source: 0001022079-17-000085 · wf-form4_148849125315160.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,748 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,759 | $95.68 | $263,981.12 |
DisclosureSEC source: 0001022079-17-000071 · wf-form4_148831860472579.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,911 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:17 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 187,845 | $0.00 Strike: $95.80 | $0.00 |
DisclosureSEC source: 0001022079-17-000051 · wf-form4_148789185983802.xml · derivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,845 Underlying: Common Stock · 187,845 shares Expires 2027-02-21 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:17 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 15,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-17-000051 · wf-form4_148789185983802.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,670 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 5,686 | $93.85 | $533,631.10 |
DisclosureSEC source: 0001022079-17-000025 · wf-form4_148719512576281.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,011 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| January 13, 2017 Filed Jan 19, 2017 00:16 UTC | XEROX CORP XRX · Entity 12016 | GrantDeferred Stock Units | 12,803 | $7.03 | $90,005.09 |
DisclosureSEC source: 0001127602-17-001957 · form4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,826 F1 · security: Each DSU represent the right to receive one share of common stock upon the reporting person's termination of service as a director. F2 · balance_after: This amount includes 205 shares paid on 7/29/16 and 259 shares paid on 10/31/16 from the reinvestment of dividend equivalents paid on Deferred Stock Units held as of 6/30/2016 and 9/30/2016, respectively. These dividend equivalents have been adjusted to reflect the effects of separation. F3 · balance_after: Reflects an antidilution adjustment to the number of DSUs that was made in connection with the legal and structural separation (the "Spin-Off") of Conduent Incorporated from Xerox Corporation ("Xerox"). The number of shares of Xerox's common stock subject to the awards was adjusted based on the number of the shares subject to the DSU awards immediately prior to the Spin-Off and (ii) the ratio of (A) the pre-Spin-Off closing price on December 30, 2016 of Xerox's common stock and (B ) the volume weighted average price of Xerox's common stock trading on the New York Stock Exchange on January 3, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.